{"nctId":"NCT01311648","briefTitle":"BAY81-8973 Pediatric Safety and Efficacy Trial","startDateStruct":{"date":"2011-06-09","type":"ACTUAL"},"conditions":["Haemophilia A"],"count":94,"armGroups":[{"label":"PTPs 0-12 years","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)"]},{"label":"PUPs/MTPs 0-<6 years","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)"]}],"interventions":[{"name":"Recombinant Factor VIII (Kovaltry, BAY81-8973)","otherNames":[]},{"name":"Recombinant Factor VIII (Kovaltry, BAY81-8973)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male\n* PTPs (previously treated patients): aged \\<= 12 years\n* PUPs (previously untreated patients) / MTPs (minimally treated patients): aged \\< 6 years\n* Severe hemophilia A defined as \\< 1% FVIII concentration (FVIII:C)\n* PTPs: \\>= 50 exposure days (EDs) with any FVIII concentrate, no current evidence of inhibitory antibody, and no history of FVIII inhibitor formation\n* PUPs: no prior exposure to any FVIII product\n* MTPs: having no more than 3 EDs with any FVIII product, no current evidence of inhibitory antibody and no history of FVIII inhibitor formation\n\nExclusion Criteria:\n\n* With another bleeding disorder that is different from Hemophilia A\n* With thrombocytopenia (platelet count \\< 100 000/mm\\^3)\n* Creatinine \\> 2x upper limit of normal or Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) \\> 5x upper limit of normal\n* Without a negative inhibitor testing at screening (except for PUPs)\n* Receiving chemotherapy, immune modulatory drugs, has received another investigational FVIII product within the last month, or received another experimental drug within the last 3 months\n* Requires any pre-medication to tolerate FVIII treatment\n* Known hypersensitivity to active substance, mouse, or hamster protein","healthyVolunteers":false,"sex":"MALE","minimumAge":"0 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Number of Total Bleeds Within 48 h","description":"Annualized number (mean +/- standard deviation) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \\[EDs\\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"2.77"},{"groupId":"OG001","value":"1.86","spread":"3.08"},{"groupId":"OG002","value":"1.9","spread":"3.3"}]}]}]},{"type":"PRIMARY","title":"Annualized Number of Total Bleeds Within 48 h","description":"Annualized number (median \\[inter-quartile range (Q1-Q3)\\]) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \\[EDs\\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"},{"groupId":"OG002","value":"0.0","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Annualized Number of Total Bleeds During Prophylaxis Treatment","description":"Annualized number (mean +/- standard deviation) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.16","spread":"5.02"},{"groupId":"OG001","value":"3.37","spread":"5.01"},{"groupId":"OG002","value":"7.1","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Annualized Number of Total Bleeds During Prophylaxis Treatment","description":"Annualized number (median \\[inter-quartile range (Q1-Q3)\\]) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"0.00"},{"groupId":"OG001","value":"0.93","spread":"0.00"},{"groupId":"OG002","value":"4.7","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Hemostatic Control During Major and Minor Surgeries","description":"For participants who underwent major or minor surgeries during the study, hemostasis during the surgeries was assessed as excellent, good, moderate or poor. Number of surgeries per assessment was summarized and reported.","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Inhibitor Development in Main Study","description":"Number of participants with confirmed positive FVIII inhibitor titer (≥ 0.6 Bethesda unit \\[BU/mL\\]) during the main study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \\> 5.0 BU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With New Inhibitor Development in Extension Study","description":"Number of participants who had not developed an inhibitor during the main study but developed an inhibitor (confirmed positive FVIII inhibitor titer \\[≥ 0.6 BU/mL\\]) during the extension study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \\> 5.0 BU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Factor VIII Recovery Values","description":"Incremental recovery of Factor VIII (FVIII) at 20-30 min after end of infusions was determined and mean recovery values were reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"0.31"},{"groupId":"OG001","value":"1.72","spread":"0.46"},{"groupId":"OG002","value":"1.76","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0.86","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0.38","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Consumption of Factor VIII in All Infusions","description":"Factor VIII (FVIII) usage/consumption was summarized for all infusions. Consumption per participant's body weight per year was calculated and reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5499.1","spread":"1996.2"},{"groupId":"OG001","value":"4679.1","spread":"1688.7"},{"groupId":"OG002","value":"2195.8","spread":"1903.6"}]}]}]},{"type":"SECONDARY","title":"Consumption of FVIII in Infusions for Prophylaxis","description":"Factor VIII (FVIII) usage/consumption was summarized for prophylaxis infusions. Consumption per participant's body weight per year was calculated and reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5224.8","spread":"1760.2"},{"groupId":"OG001","value":"4492.7","spread":"1667.6"},{"groupId":"OG002","value":"1486.6","spread":"963.3"}]}]}]},{"type":"SECONDARY","title":"Consumption of FVIII in Infusions for the Treatment of Bleeds","description":"Factor VIII (FVIII) usage/consumption was summarized for infusions used to treat breakthrough bleeds. Consumption per participant's body weight per year was calculated and reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457.07","spread":"526.87"},{"groupId":"OG001","value":"391.64","spread":"219.61"},{"groupId":"OG002","value":"835.4","spread":"1926.4"}]}]}]},{"type":"SECONDARY","title":"Number of Infusions Per Bleed","description":"The number of infusions used to treat a bleed was defined as the first infusion to treat the bleed plus all follow-up infusions to treat the same bleed, if any. The mean value of number of infusions for each bleed was calculated and reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.8"},{"groupId":"OG001","value":"1.4","spread":"1.7"},{"groupId":"OG002","value":"1.7","spread":"8.7"}]}]}]},{"type":"SECONDARY","title":"Response to Treatment of Bleeds","description":"Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Percentage of bleeds per assessment was summarized and reported.","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"27","spread":null}]},{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"56","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Half-life (t1/2) of BAY81-8973 in Plasma","description":"Half-life (t1/2) of BAY81-8973 in plasma was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"39.7"},{"groupId":"OG001","value":"12.1","spread":"16.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Pyrexia","Nasopharyngitis","Cough","Vomiting","Diarrhoea"]}}}